From empiric testing to rational design: two decades of progress in phase I trials
Ensuring equitable access to innovative treatments is now the major challenge in oncology, says Prof. Alex Adjei
How to bridge the gap between academia and industry
Shared interests, mutual gain, flexibility and trust are key to building win–win partnerships in drug development.
Milestone in hereditary breast cancer: PARP inhibition benefits women with early-stage disease
Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women
Momentous achievements in oncology treatment: where will the wave of innovation take cancer care?
Efficacy of targeted therapies has enabled unprecedented survival gains in the last few years, but Prof. Jean-Charles Soria believes overcoming drug resistance is likely to be a local battle fought in the tumour microenvironment
CAR-T cell therapy in solid tumours: will we ever replicate the success rates achieved in blood cancers?
Despite early promises, advances are needed in targeting tumour-specific epitopes, overcoming the tumour microenvironment, and automating CAR-T production, explains Prof. Ulrike Köhl